Overview

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Part B).
Phase:
Phase 1
Details
Lead Sponsor:
Alnylam Pharmaceuticals